• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Two bedaquiline-containing regimens had superior efficacy and safety profiles for treatment of rifampin-resistant tuberculosis

byJessie WillisandTeddy Guo
December 7, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to a 9-month injectable-containing (control) regimen, both bedaquiline-containing oral regimens had more favourable outcomes, such as negative cultures.

2. There were additionally less cases of hearing loss in the bedaquiline regimens compared to the control regimen.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Rifampin-resistant tuberculosis (TB) threatens the global effort to eradicate tuberculosis. This randomized control trial evaluated two short regimens containing a new drug for tuberculosis, bedaquiline. The objective of STREAM stage 2 was to evaluate the 9-month bedaquiline-containing regimen compared to the 9-month regimen used in STREAM stage 1. Patients with confirmed pulmonary TB were randomized to four drug regimens: a long regimen recommended by WHO (which was terminated early), a control regimen (used in STREAM stage 1), an oral regimen containing bedaquiline, and a 6-month regimen containing bedaquiline. This study found that both bedaquiline-containing regimens had more favourable outcomes compared to the control regimen. The overall incidence of grade 3-4 adverse events was comparable between groups. There were additionally fewer cases of hearing loss with the bedaquiline-containing regimens compared to the control group. Limitations of this study include the open-label design for both investigators and participants. Nonetheless, this study provides evidence to support the superiority of bedaquiline-containing regimens against rifampin-resistant TB with reduced cases of ototoxicity.

Click to read the study in the Lancet

Relevant Reading: An all-oral 6-month regimen for multidrug-resistant TB (the NExT study): a multicenter, randomized controlled trial.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 25

The Scan by 2 Minute Medicine®: Company Cuts TB Testing Cost, Guillain-Barre Syndrome Struggles for Stevens, Medical Abortion Tests, and Blood Supply Shortages

#VisualAbstract: Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India

In-Depth [randomized controlled trial]: The STEAM stage 2 trial was a randomized phase 3 trial that evaluated two standardized regiments for the treatment of rifampin-resistant tuberculosis (TB). Patients were eligible if they were aged 15 years or older and confirmed pulmonary TB with evidence of rifampin resistance. A total of 588 were randomized 1:2:2:2 to either a long regimen, control regimen, oral regimen 9-month and 6-month regimen. The long regimen (n=32) was a 20-month regimen recommended by WHO, which was terminated early. The control regimen (n=202) was a 9-month regimen of high-dose moxifloxacin, clofazimine, ethambutol and pyrazinamide for 40 weeks and high-dose isoniazid and protionamide given for 16 weeks in an intensive phase. The oral regimen (n=211) consisted of the 9-month control regimen except that kanamycin was replaced by bedaquiline and levofloxacin replaced moxifloxacin. The 6-month regimen (n=143) was bedaquiline, clofazimine, pyrazinamide and levofloxacin for 28 weeks with high-dose isoniazid with kanamycin for 8 weeks during an intensive phase. The control regimen was changed in 2018 with levofloxacin replacing moxifloxacin in the control regimen given QT prolongation. The study was not blinded.

The primary outcome was negative cultures for TB without a preceding unfavourable event (death, bacteriological failure or recurrence, major treatment change) at 72 weeks. Study results demonstrated a total of 133 (71%) of 187 of the control regimen and 162 (83%) of 196 of the oral regimen had favourable outcomes (adjusted difference 11.0%, 95% CI 2.9-19.0, p<0.0001 for non-inferiority). A total of 122 (91%) of 134 of the 6-month regimen and 87 (69%) of 127 of the concurrent control regimen had favourable outcomes (adjusted difference 22.2%, 13.1-31.2). At 76 weeks, grade 3 or 4 adverse events occurred in 53% of the control regimen, 50% of the oral regimen, and 55% of the 6-month regimen. There were more cases of hearing loss in the control regimen compared to the oral regimen (9% vs 2%, p=0.0015).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antituberculosis treatmentBedaquilineclofaziminefluoroquinoloneIsoniazidlevofloxacinmoxifloxacinmultidrug-resistant tuberculosismultidrug-resistant tuberculosis (MDR-TB)mycobacterium tuberculosispyrazinamiderifampinrifampin-resistant tuberculosistuberculosis
Previous Post

Discontinuing RAS inhibitors in advanced chronic kidney disease does not impact long-term outcomes

Next Post

Extended rivaroxaban treatment reduces recurrence rate for patients with deep vein thrombosis

RelatedReports

The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 25

October 5, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Company Cuts TB Testing Cost, Guillain-Barre Syndrome Struggles for Stevens, Medical Abortion Tests, and Blood Supply Shortages

October 3, 2023
#VisualAbstract: Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India
StudyGraphics

#VisualAbstract: Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India

August 15, 2023
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Infectious Disease

Rifapentine effective in preventing leprosy in household contacts

June 1, 2023
Next Post
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Extended rivaroxaban treatment reduces recurrence rate for patients with deep vein thrombosis

#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

#VisualAbstract: Vitamin D supplementation is not preventative for statin-associated muscle symptoms or statin discontinuation

Shared decision-making tool for antidepressants improves patient and physician satisfaction

Wellness Check: Mental Health

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Seriesâ„¢ textbook.

Subscription Options

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Specific viruses may be associated with increased risk and worse outcomes of ovarian cancer
  • Low-dose amitriptyline effective and well-tolerated for management of irritable bowel syndrome
  • Patisiran prevents functional decline in patients with cardiac amyloidosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classicsâ„¢
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options